d.pro-c.me Open in urlscan Pro
84.207.240.85  Public Scan

Form analysis
0 forms found in the DOM

Text Content

THIS CONTENT WAS DESIGNED FOR
PORTRAIT ORIENTATION ONLY.



0.5 Credit(s)


CALCITROPES, MYOTROPES, AND MITOTROPES: THE ROLE OF EMERGING THERAPIES TO
IMPROVE SYSTOLIC FUNCTION IN HFREF

Please complete and tap PROCEED at the end to submit and continue.


QUESTION 1 OF 4

How often do you currently apply the unique mechanisms of action of cardiac
myotropes and clinical evidence regarding their safety and efficacy in the
treatment of heart failure with reduced ejection fraction?

   
   
 * Always
   
   
   
 * Frequently
   
   
   
 * Sometimes
   
   
   
 * Rarely
   
   
   
 * Never
   
   
   
 * N/A
   
   


QUESTION 2 OF 4

In patients with heart failure with reduced ejection fraction (HFrEF),
clinically available cardiac calcitropes have been associated with:

   
   
 * Increased mortality
   
   
   
 * Decreased cardiac contractility
   
   
   
 * Decreased heart failure hospitalizations
   
   
   
 * Decreased mortality
   
   


QUESTION 3 OF 4

Pharmacological agents that improve myocardial performance by affecting the
molecular motor and scaffolding of the myocardial contractile apparatus are:

   
   
 * Cardiac calcitropes
   
   
   
 * Cardiac glycosides
   
   
   
 * Mitotropes
   
   
   
 * Myotropes
   
   


QUESTION 4 OF 4

Which of the following is true regarding the recently published results of the
GALACTIC-HF trial which compared omecamtiv mecarbil verses placebo in patients
with HFrEF?

   
   
 * There was a significant difference between groups in the change from baseline
   on the Kansas City Cardiomyopathy Questionnaire total symptom score.
   
   
   
 * Omecamtiv mecarbil statistically significantly reduced the risk of the
   primary composite outcome of first heart failure event or cardiovascular
   death.
   
   
   
 * Omecamtiv mecarbil had no effect on heart rate or N-terminal of the
   prohormone brain natriuretic peptide (NT-proBNP).
   
   
   
 * The frequency of cardiac ischemic and ventricular arrhythmia events was
   elevated in the omecamtiv mecarbil group.
   
   




PROGRESS

PRETEST



MATTERS OF THE HEART: UNMET NEEDS IN HEART FAILURE WITH REDUCED EJECTION
FRACTION (HFREF) - MITCHELL A. PSOTKA, MD, PHD



EMERGING HFREF THERAPIES: A LOOK AT THE CLINICAL EVIDENCE - JOHN R. TEERLINK, MD



POSTTEST




CME INFORMATION

EDUCATIONAL RESOURCES

SHARE THIS PRESENTATION

MORE FROM VINDICO

ACCREDITED BY

This continuing medical education activity is provided by

STATEMENT OF COMMERCIAL SUPPORT

This activity is supported by an educational grant from Cytokinetics, Inc.

ACTIVITY CHAIR

John R. Teerlink, MD, FACC, FAHA, FESC, FHFA, FHFSA, FRCP(UK)
Professor of Medicine, University of California San Francisco
Director, Heart Failure Program
Director, Echocardiography
San Francisco VA Medical Center
San Francisco, CA

Consulting Fee: Abbott Medical Optics, Amgen, AstraZeneca, Bayer, Boehringer
Ingelheim, Bristol Myers Squibb, Cytokinetics, Medtronic, Merck, Novartis
Contracted Research: Abbott Medical Optics, Amgen, AstraZeneca, Bayer,
Boehringer Ingelheim, Bristol Myers Squibb, Cytokinetics, Medtronic, Novartis

FACULTY

Mitchell A. Psotka, MD, PhD, FACC, FHFSA
Director, Infiltrative Cardiomyopathy Center
Associate Director, Heart Failure Research
Inova Heart and Vascular Institute
Falls Church, VA

Consulting Fee: Amgen, Cytokinetics, Windtree

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical
Affairs and Compliance.

Privacy Policy | Feedback

This site uses cookies. Learn More.